WCG adds clinical trial benchmarking firms to portfolio

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Kritchanut)
(Image: Getty/Kritchanut)

Related tags: WCG, Benchmarking, Clinical trials, CRO, Contract research organization, Contract research

WCG’s acquisition of KMR Group and MCC addresses sponsor and CRO need to establish a common set of metrics to understand and manage clinical trial performance, says CEO.

KMR Group and Metrics Champion Consortium (MCC) will operate independently as part of the WIRB-Copernicus Group (WCG) Market Insights and Intelligence Division. The firms provide benchmarking, metrics, analytics and performance management in the clinical research and development space.

WCG will support the companies with access to capital, expertise, and corporate operational support, according to the clinical services organization.

“The sheer volume of clinical trial performance data available to sponsors and CROs has exploded over the past few years and many clinical trial leaders are struggling to operationalize these data in a consistent and actionable manner,”​ said Donald A. Deieso, PhD, executive chairman and CEO of WCG.

To keep up, Deieso told us “sponsors and CROs need to establish a common set of metrics to understand and manage clinical trial performance.”

“By bringing together these leading companies, we can address the growing need to establish standardized data benchmarks across the most critical areas of R&D and clinical trial execution.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars